- Home
- DMRC vs MSLE Comparison
DMRC vs MSLE Comparison
Compare DMRC & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMRC | MSLE |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 186.9M |
| IPO Year | 2026 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DMRC | MSLE |
|---|---|---|
| Price | $7.22 | $6.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $11.50 | ★ $24.17 |
| AVG Volume (30 Days) | ★ 147.9K | 64.2K |
| Earning Date | 11-06-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.07 | $5.44 |
| 52 Week High | $17.47 | $13.39 |
Technical Indicators
Market Signals| Indicator | DMRC | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | 32.08 |
| Support Level | $7.06 | $5.52 |
| Resistance Level | $8.20 | $10.58 |
| Average True Range (ATR) | 0.46 | 0.58 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 61.17 | 7.39 |
Price Performance
Historical ComparisonAbout DMRC Digimarc Corporation
Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.